VIENNA, Austria, Dec. 22, 2021 (GLOBE NEWSWIRE) -- AFFiRiS AG, a clinical-stage biotechnology company developing novel disease-modifying Specific Active Immunotherapies (SAITs), today announced an exclusive collaboration and license agreement with Frontier Biotechnologies Inc. (688221.SH), a commercial-stage biopharmaceutical company, for the development and commercialization of AFFITOPE® AT04 for the treatment of patients with hypercholesterolemia in the Greater China region, including mainland China, Hong Kong, Macau and Taiwan. AFFITOPE® AT04 is a potential first-in-class investigational active immunotherapy targeting PCSK9, with results of a large phase 1 clinical study having recently been published. Shanghai-based Lynx Financial served as the sole financial advisor in this transaction.
AFFiRiS: Positive phase 1 results with immunotherapies targeting PCSK9 to treat hypercholesterolemia published by the European Journal of Clinical Pharmacology
AFFiRiS, a clinical-stage biotechnology company developing novel disease-modifying specific immunotherapies, announces the presentation of in vivo data with its antibody mAB C6-17 against the mutant huntingtin protein (mtHTT) at the 16th Annual Huntington's Disease Therapeutics Conference.
VIENNA, Austria, April 27, 2021 (GLOBE NEWSWIRE) -- AFFiRiS, a clinical-stage biotechnology company developing novel disease-modifying specific immunotherapies, announces today the presentation of in vivo data with its antibody mAB C6-17 against the mutant huntingtin protein (mtHTT) at the 16th Annual Huntington's Disease Therapeutics Conference. The Conference will be held virtually April 27 – 29, 2021 and will cover all aspects of drug discovery and development for Huntington's disease (HD).
AFFiRiS Announces FDA Response to its pre-IND Submission for Phase 2 trial with AFFITOPE PD01 in Early Parkinson's Disease Patients